BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 52 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $115,000 | +109423.8% | 118,000 | +10.3% | 0.01% | +16.7% |
| Q2 2023 | $105 | +1.0% | 107,000 | +5.9% | 0.01% | 0.0% |
| Q1 2023 | $104 | -2.8% | 101,000 | 0.0% | 0.01% | -14.3% |
| Q4 2022 | $107 | -99.9% | 101,000 | +16.1% | 0.01% | +16.7% |
| Q3 2022 | $86,000 | +26.5% | 87,000 | +26.1% | 0.01% | +20.0% |
| Q2 2022 | $68,000 | -1.4% | 69,000 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $69,000 | +30.2% | 69,000 | +35.3% | 0.00% | +33.3% |
| Q4 2021 | $53,000 | +6.0% | 51,000 | +4.1% | 0.00% | -40.0% |
| Q3 2021 | $50,000 | – | 49,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |